Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Cabaletta Bio Inc CABA

Healthcare Biotechnology
Cabaletta Bio, Inc. is a clinical-stage biotechnology company. The Company is focused on the discovery and development of engineered T cell therapies that have the potential to provide deep and durable, perhaps curative, responses with one-time administration for patients with autoimmune diseases. Its Cabaletta Approach to B cell Ablation (CABA) platform encompasses two strategies: Chimeric... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:CABA)

Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

GlobeNewswire March 21, 2024

Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Systemic Sclerosis

GlobeNewswire March 20, 2024

Cabaletta Bio to Participate in Upcoming Investor Conferences in March

GlobeNewswire February 27, 2024

Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Myositis

GlobeNewswire February 1, 2024

Cabaletta Bio to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

GlobeNewswire January 31, 2024

Cabaletta Bio Receives Additional FDA Fast Track Designations for CABA-201 in Dermatomyositis and Systemic Sclerosis

GlobeNewswire January 8, 2024

Cabaletta Bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 2, 2024

Cabaletta Bio to Participate in the 6th Annual Evercore ISI HealthCONx Conference

GlobeNewswire November 28, 2023

Cabaletta Bio Reports Third Quarter 2023 Financial Results and Provides Business Update

GlobeNewswire November 9, 2023
View More News ››

Opinion & Analysis (NDAQ:CABA)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:CABA)

RE:Looks interesting

A really nice run here.  Took some profit out though
mevani - August 3, 2020

Looks interesting

Took a starter postion here on the dip.   I have a feeling this will find its way back up soon. 
mevani - May 15, 2020
View more Bullboard ››

SKRR Exploration Inc.

SKRR Exploration Inc.

SKRR Exploration Inc. is a Canada-based precious metal explorer with properties in Saskatchewan mining jurisdictions. The ...
View More »